Important note: Information in this article was accurate in 2004. The state of the art may have changed since the publication date.
|
|
British Medical Journal (12.04.04) Vol. 329; P. 1308 - Wednesday, December 29, 2004
Owen Dyer
The potential effect of the agreement on India's generic drug industry - which produces most of the generic, fixed-dose combination antiretroviral drugs DWB now uses - troubles Dr. Rowan Gillies, DWB's international president. "We're not ideologically attached to generics, but we've found it's what works best. At the moment, only generics can provide a treatment regimen of just two pills a day. That's essential for compliance and good results," said Gillies. DWB now treats 23,000 HIV patients in 27 countries in Asia, Africa, Latin America, and Eastern Europe - double the patients it treated last year.
"We're gravely concerned that our sources of affordable medicines will dry up," said Gillies. "Not only are patents going to be granted on all new medicines, some existing medicines that we rely on will be reviewed for possible patent protection as well," he said.
The two-year survival rate for patients in DWB's Malawi program is 85 percent, said Dr. Arnaud Leannin of DWB's AIDS program there. But growing numbers of patients are now failing first-line treatment, said Pietro di Mattei, medical coordinator of DWB's Mozambique AIDS program. Switching to second-line therapy raises the per-patient cost from $250 a year to $700-$3,000. Second-line drugs adapted to resource- poor settings are needed, he said.
041229
AD042624
Copyright © 2004 - Information, Inc., Bethesda, MD. The CDC National Center for HIV, STD and TB Prevention provides the following information as a public service only. Providing synopses of key scientific articles and lay media reports on HIV/AIDS, other sexually transmitted diseases and tuberculosis does not constitute CDC endorsement. This daily update also includes information from CDC and other government agencies, such as background on Morbidity and Mortality Weekly Report (MMWR) articles, fact sheets, press releases and announcements. Reproduction of this text is encouraged; however, copies may not be sold, and the CDC HIV/STD/TB Prevention News Update should be cited as the source of the information. Contact the sources of the articles abstracted below for full texts of the articles.
AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Elton John AIDS Foundation, the National Library of Medicine, AIDS Walk of Orange County, and donations from users like you.
Always watch for outdated information. This article first appeared in 2004. This material is designed to support, not replace, the relationship that exists between you and your doctor.AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.
Copyright ©1980, 2004. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content.
.